NASDAQ · LPCN
Healthcare · Biotechnology
$1.45
Up+$0.01 (+0.69%)
Updated Oct 27, 2026, 5:17 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LPCN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
LPCN closed at $1.45 after 21 trading sessions, down 30.62% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $1.44 | $1.45 | $1.40 | $1.45 | 108.94K |
| Oct 23, 2026 | $1.42 | $1.48 | $1.41 | $1.44 | 218.66K |
| Oct 22, 2026 | $1.56 | $1.60 | $1.43 | $1.46 | 354.88K |
| Oct 21, 2026 | $1.59 | $1.64 | $1.5807 | $1.60 | 160.67K |
| Oct 20, 2026 | $1.54 | $1.66 | $1.5374 | $1.62 | 246.5K |
| Oct 19, 2026 | $1.51 | $1.57 | $1.40 | $1.53 | 323.66K |
| Oct 16, 2026 | $1.66 | $1.68 | $1.48 | $1.56 | 407.32K |
| Oct 15, 2026 | $1.64 | $1.69 | $1.59 | $1.68 | 267.18K |
| Oct 14, 2026 | $1.69 | $1.71 | $1.60 | $1.69 | 374.29K |
| Oct 13, 2026 | $1.64 | $1.74 | $1.61 | $1.62 | 501.79K |
| Oct 12, 2026 | $1.705 | $1.77 | $1.59 | $1.66 | 884.4K |
| Oct 9, 2026 | $1.89 | $1.90 | $1.72 | $1.72 | 1.06M |
| Oct 8, 2026 | $2.05 | $2.05 | $1.89 | $1.93 | 2.32M |
| Oct 7, 2026 | $2.95 | $3.15 | $2.07 | $2.20 | 105.84M |
| Oct 6, 2026 | $2.08 | $2.10 | $2.0699 | $2.10 | 12.78K |
| Oct 5, 2026 | $2.07 | $2.135 | $2.07 | $2.07 | 19.76K |
| Oct 2, 2026 | $2.08 | $2.13 | $2.05 | $2.05 | 38.94K |
| Oct 1, 2026 | $2.19 | $2.19 | $2.07 | $2.07 | 71.21K |
| Sep 30, 2026 | $2.14 | $2.25 | $2.08 | $2.20 | 31.37K |
| Sep 29, 2026 | $2.09 | $2.21 | $2.09 | $2.16 | 24.26K |
| Sep 28, 2026 | $2.07 | $2.21 | $2.06 | $2.09 | 34.44K |
The latest Smart Investors Daily articles mentioning LPCN.
Company
Market Activity
Research & News
LPCN research
Company profile and research snapshot.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | HC Wainwright & Co. | Neutral | — |
| Apr 6, 2026 | HC Wainwright & Co. | Neutral | — |
| Jan 21, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 13, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 7, 2026
Health Canada approved TLANDO for testosterone replacement therapy in adult men with hypogonadism, with Lipocine’s commercial partner Verity Pharma targeting a Canadian launch by the end of 2026. Key Investor TakeawaysLipocine (NASDAQ:LPCN) secured Health Canada approval for TLANDO, expanding the oral testosterone therapy’s geographic reach into Canada.
Yahoo · Oct 7, 2026
Investing.com -- Lipocine Inc (NASDAQ:LPCN) shares rose 30% in premarket trading Wednesday after Health Canada approved the company's oral testosterone drug TLANDO.
Yahoo · Oct 7, 2026
Health Canada approves Lipocine’s oral testosterone replacement therapy Tlando.
Yahoo · Oct 7, 2026
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through Lipocine's licensing partner Verity Pharmaceuticals Inc (Verity Pharma), Health Canada has approved TLANDO® (testosterone undecanoate) capsules for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of endogenous testosterone (male hypogonadism). Verity Pharma holds exclusive commercial rights
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LPCN.
